{
    "2021-12-31": [
        [
            {
                "time": "2021-12-31",
                "original_text": "2021收官日！NMPA再批3款1类新药，恒瑞下了“双黄蛋”！",
                "features": {
                    "keywords": [
                        "NMPA",
                        "1类新药",
                        "恒瑞医药",
                        "双黄蛋"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "年终盘点|2021年十大\"争议\"白马股",
                "features": {
                    "keywords": [
                        "年终盘点",
                        "争议",
                        "白马股"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "国家药监局批准恒瑞医药脯氨酸恒格列净片上市",
                "features": {
                    "keywords": [
                        "国家药监局",
                        "恒瑞医药",
                        "脯氨酸恒格列净片"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药脯氨酸恒格列净片、羟乙基磺酸达尔西利片获批上市",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "脯氨酸恒格列净片",
                        "羟乙基磺酸达尔西利片"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "2021年A股年终盘点：十大“水逆”板块在哪里？",
                "features": {
                    "keywords": [
                        "A股",
                        "年终盘点",
                        "水逆",
                        "板块"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "21硬核研报丨2022医药行业投资前瞻：创新药出海潮来临 “卖水人”CXO高景气值得期待",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资前瞻",
                        "创新药",
                        "CXO",
                        "高景气"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药：公司目前已上市创新药注射用卡瑞利珠单抗、硫培非格司亭均属于生物制药",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "创新药",
                        "卡瑞利珠单抗",
                        "硫培非格司亭",
                        "生物制药"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药：PD-1联合阿帕替尼治疗晚期肝癌的海外三期临床试验目前进展顺利",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "PD-1",
                        "阿帕替尼",
                        "肝癌",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "400余家药企研发人员已超16.7万，研发速度不断提升",
                "features": {
                    "keywords": [
                        "药企",
                        "研发人员",
                        "研发速度"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-30",
                "original_text": "A股融资融券日报：两融余额增加32.82亿元（12月30日）",
                "features": {
                    "keywords": [
                        "A股",
                        "融资融券",
                        "两融余额"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "中国医药产业迎来“创新药”时代 401家公司研发人员超16.7万",
                "features": {
                    "keywords": [
                        "医药产业",
                        "创新药",
                        "研发人员"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "医改进入“深水区” 新政频出药企如何应对行业大变局？",
                "features": {
                    "keywords": [
                        "医改",
                        "新政",
                        "药企",
                        "行业变局"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}